0 results for 'Skadden, Arps, Slate, Meagher & Flom LLP'
Calif. Appellate Court Declares Delaware Exclusive Forum Provision Unenforceable
Publicly traded corporations increasingly adopted exclusive forum provisions to reduce the risk of burdensome and costly multijurisdictional stockholder litigation. State and federal courts around the country regularly enforced the provisions, dismissing cases not brought in the specified jurisdiction.
Big Law's Return-to-Office Journey Still Not Complete, but More Settled Now
"The overwhelming majority of our colleagues are complying," noted Davis Polk's Neil Barr. "I know not everyone loves it, but from the institution's perspective, we are in a good spot."
Four Lessons From Delaware Corporate Litigation You Should Have Learned in 2023
The Court of Chancery and Delaware Supreme Court hammered home several key points multiple times throughout 2023, signaling to litigators that they may want to keep them in mind as they head into the new year.
Linklaters London Capital Markets Partner Walks to Reed Smith
The move comes just days after the firm parted ways with a partner duo bound for Paul Weiss and Skadden.
Law Journal Press | Digital Book
District of Columbia Legal Malpractice Law 2024
Authors: Shari L. Klevens, Alanna G. Clair
View this Book
View more book results for the query "Skadden, Arps, Slate, Meagher & Flom LLP"
Do Distributed Firm Partners Pine for Profit-Sharing?: The Morning Minute
The news and analysis you need to start your day.
$3.5M Verdict Marks Fifth Consecutive Win for Roundup Plaintiffs
Roundup plaintiffs notched another win Dec. 5, with a $3.5 million verdict in Philadelphia.
The Fast (and Strange) Rise of the Legal Influencer
Despite much cynicism and a recent controversy, top lawfluencers explain how to maintain a sound social media profile, and why it is worth the flack.
Simpson Thacher to Require Four Days in Office in 2024
In-office mandate adherence will be a factor in overall pay for Simpson personnel, with the firm saying noncompliance could affect compensation, sources said.
Upping the Dosage: Health Care and Pharmaceuticals Antitrust Regulation in 2023
Antitrust developments in the health care and pharmaceutical industries were exceptionally active in 2023. From the FTC's challenge of a merger between Amgen and Horizon Therapeutics, to joint agency withdrawal of well-established health care merger policy statements, to agency interest in pharmacy benefit managers, the authors review some of the most notable antitrust activity in the health care and pharmaceutical industries over the past year.Trending Stories
- 1Few Big Law Firms With Single-Tier Partnerships Are Left. They Aren't Talking About It.
- 2AI/IP Issues Part 2: What Current Litigation Can Tell Us About Where IP in AI Is Heading
- 3Biden Will Be First Lawyer-President Without a JD From the 'T-14' in a Century
- 4'Contributed to National Strife': Rudy Giuliani Is Disbarred on Manhattan Court's Order
- 5Which Law Firms Are On Course to be in the Global Elite?
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250
More from ALM
- Morgan & Morgan Class Action Attorneys Detail Pathway to Success Within Cybersecurity and Data Privacy Practice 1 minute read
- Holwell Shuster & Goldberg Partners Leverage 'Hostile' Witnesses to Secure $101 Million Verdict Against Walmart 1 minute read
- Legal Speak at General Counsel Conference Midwest 2024: Mike Andolina, Partner, White & Case 1 minute read
Resources
Blueprint for Successful Second Request Document Review
Brought to you by Integreon
Download Now
Employee Happiness Playbook: The 3 R's for Business Success in 2024
Brought to you by Amazing Workplace, Inc.
Download Now
The Positive Impact of AI at Small Law Firms: 4 Key Insights
Brought to you by LexisNexis®
Download Now
Will Generative AIs Transform Legal Services? Defensibility and Security Must Be a Focus
Brought to you by HaystackID
Download Now